ARF like GTPase 2 binding protein pseudogene 3Genealiases: []
Q-omics provides the consensus-scored ARL2BPP3 profile across patient tissues and cancer cell-line models. ARL2BPP3 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ARL2BPP3 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, ARL2BPP3 RNA expression shows 5,443 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, and STAD as cancer lineages where ARL2BPP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL2BPP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL2BPP3 survival associations across molecular data types. ARL2BPP3 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL2BPP3 RNA expression–survival associations across cancer types. High ARL2BPP3 expression shows unfavorable associations in READ, PAAD, BRCA, THCA, MESO and LUAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for ARL2BPP3 RNA expression.
This table summarizes ARL2BPP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for ARL2BPP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL2BPP3 shows lower tumor expression in STAD. The STAD box plot shows higher ARL2BPP3 RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p = .030).
This table shows molecular features associated with ARL2BPP3 in patient tissues and cancer cell lines. In patient samples, ARL2BPP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
